Trastuzumab: tested on its own

81 studies: no other medicine in its arm. Page 1 of 1. Open to participants first (1), then studies with results posted, then the rest; newest registration first within each.

• Phase II Trial of Anti-HER2 Treatment in HER2-enriched Early Breast Cancer Identified by PAM50 (HER2E-PAM, PAMILIA Study)RecruitingNCT04817540Phase 2Report a problem
• Extension Study to Provide Adjuvant Treatment Following Neoadjuvant Treatment and Surgical Resection in Protocol TX05-03CompletedNCT04109391Phase 3Results postedReport a problem
• A Study to Demonstrate the Equivalent Pharmacokinetic Properties of a Single Intravenous Dose of HD201 and EU-Herceptin® and US-Herceptin® in Healthy Male SubjectsCompletedNCT03776240Phase 1Results postedReport a problem
• Efficacy and Safety of Trastuzumab Biosimilar (Herzuma®) Plus Treatment of Physician's Choice (TPC) in Patients With HER-2 Positive Metastatic Breast CancerCompletedNCT03755141Phase 2Results postedReport a problem
• A Continuation Study of Herceptin (Trastuzumab) in Participants With Metastatic or Locally Advanced CancerCompletedNCT02721641Phase 3Results postedReport a problem
• Efficacy and Safety Evaluating Study of CT-P6 in Her2 Positive Early Breast CancerCompletedNCT02162667Phase 3Results postedReport a problem
• A Study to Compare the Effect of SB3 and Herceptin® in Women With HER2 Positive Breast CancerCompletedNCT02149524Phase 3Results postedReport a problem
• Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of SB3 in Healthy Male SubjectsCompletedNCT02075073Phase 1Results postedReport a problem
• A Study of Herceptin (Trastuzumab) Monotherapy in Patients With Metastatic Urothelial CancerTerminatedNCT02013765Phase 2Results postedReport a problem
• A Study of Herceptin (Trastuzumab) in Patients With Metastatic or Advanced Gastric Cancer With Disease ProgressionTerminatedNCT02005484Phase 2Results postedReport a problem
• A Study of Subcutaneous At Home Administration of Trastuzumab (Herceptin) in Participants With Human Epidermal Growth Factor Receptor 2-positive (HER2+) Early Breast Cancer (eBC)CompletedNCT01926886Phase 3Results postedReport a problem
• Phase III to Evaluate Patient´s Preference of Subcutaneous Trastuzumab vs Intravenous in HER2+ Advanced Breast CancerCompletedNCT01875367Phase 3Results postedReport a problem
• A Safety and Tolerability Study of Assisted and Self-Administered Subcutaneous (SC) Herceptin (Trastuzumab) as Adjuvant Therapy in Early Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast CancerCompletedNCT01566721Phase 3Results postedReport a problem
• Participant Preference of Subcutaneous (SC) Versus Intravenous (IV) Herceptin (Trastuzumab) in Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast CancerCompletedNCT01401166Phase 2Results postedReport a problem
• Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous CancerCompletedNCT01367002Phase 2Results postedReport a problem
• A Study of Herceptin (Trastuzumab) in Combination With Whole Brain Radiotherapy in Patients With HER-2 Positive Breast CancerTerminatedNCT01363986Phase 2Results postedReport a problem
• Intrathecal Trastuzumab for Leptomeningeal Metastases in HER2+ Breast CancerCompletedNCT01325207Phase 1/2Results postedReport a problem
• A Study of Herceptin (Trastuzumab) in Combination With Standard Chemotherapy in Patients With HER Positive Metastatic Gastric CancerTerminatedNCT01260194Phase 4Results postedReport a problem
• A Dose-Finding Study of Subcutaneous Herceptin (Trastuzumab) in Healthy Male Volunteers and Human Epidermal Growth Factor Receptor 2 (HER2)-Positive FemalesCompletedNCT00800436Phase 1Results postedReport a problem
• Trastuzumab in Treating Older Women With Early-Stage Breast CancerCompletedNCT00796978Phase 2Results postedReport a problem
• Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone LumpectomyCompletedNCT00769379Phase 3Results postedReport a problem
• Use of Trastuzumab to Induce Increased ER Expression in ER-negative/Low, Her-2/Neu Positive Breast CancerTerminatedNCT00726180Phase 1/2Results postedReport a problem
• Neoadjuvant Herceptin for Ductal Carcinoma In Situ of the BreastCompletedNCT00496808Not applicableResults postedReport a problem
• Trastuzumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer or Bile Duct Cancer That Cannot Be Removed by SurgeryTerminatedNCT00478140Phase 2Results postedReport a problem
• Herceptin (Trastuzumab) in Treating Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Primary Breast CancerCompletedNCT00045032Phase 3Results postedReport a problem
• A Study to Assess the Bioequivalence of Trastuzumab Via Different Subcutaneous Delivery Platforms in Healthy Male ParticipantsCompletedNCT07214766Phase 1Report a problem
• A Study to Compare PK, Immunogenicity and Safety of Trastuzumab of Incepta Pharmaceuticals Ltd With Trastuzumab (Roche)CompletedNCT06886659Phase 1Report a problem
• To Compare the Pharmacokinetics, Safety, and Immunogenicity of Subcutaneous CT-P6 and Herceptin in Healthy Male Subjects (Trastuzumab)CompletedNCT06687928Phase 1Report a problem
• Clinical Study to Compare the Pharmacokinetics and Safety of Trastuzumab for Injection With Herceptin® in Healthy Male VolunteersCompletedNCT05765357Phase 1Report a problem
• A Study of Trastuzumab and Pyrotinib in HER2 Positive Locally Advanced or Metastatic Urothelial CarcinomaStatus unknownNCT05318339Phase 2Report a problem
• Trastuzumab and Standard Treatment With Chemo- and Immunotherapy as First Line Treatment for HER2 Positive Esophageal Squamous Cell Carcinoma PatientsStatus unknownNCT05170256Phase 2Report a problem
• Evaluating 6-months of HER2-targeted Therapy in Patients With HER2 Positive Early-stage Breast Cancer That Achieve a Pathological Complete Response to Neoadjuvant Systemic TherapyActive, not recruitingNCT04928261Phase 4Report a problem
• A Safety and Pharmacokinetic Study Between HLX02 and Herceptin®(US-licensed and EU-approved) in Healthy Chinese Male SubjectsCompletedNCT04670796Phase 1Report a problem
• Trastuzumab to Patients With Advanced Gastric Cancer With HER2 Positive Expression in CTCTerminatedNCT04168931Phase 2Report a problem
• Phase II Study of Herzuma® Plus Gedatolisib in Patients With HER-2 Positive Metastatic Breast CancerStatus unknownNCT03698383Phase 2Report a problem
• Trastuzumab in HER2-positive Biliary Tract CancerCompletedNCT03613168Phase 2Report a problem
• Efficacy and Safety Study of EG12014 Compared With Herceptin in Subjects With HER2 Positive Early Breast CancerCompletedNCT03433313Phase 3Report a problem
• A Comparing Study Between ALT02(Trastuzumab Biosimilar) and Herceptin® in Healthy SubjectsCompletedNCT03242239Phase 1Report a problem
• A Pharmacokinetic Study Comparing EG12014 and Herceptin (Trastuzumab) in Healthy Male VolunteersCompletedNCT03180242Phase 1Report a problem
• Study Comparing Pharmacokinetics, Safety and Immunogenicity of CT-P6 and US-licensed HerceptinCompletedNCT02665637Phase 1Report a problem
• Phase 1 Study of Trastuzumab Administered as a Single Intravenous InfusionCompletedNCT02594761Phase 1Report a problem
• A Safety and Pharmacokinetic Study Between HLX02 and Herceptin®(U.S. and German Sourced) in Healthy Chinese Male SubjectsCompletedNCT02581748Phase 1Report a problem
• Bioequivalence Study Evaluating the Pharmacokinetics of DMB-3111 and Trastuzumab in Healthy Japanese Male AdultsCompletedNCT02100917Phase 1Report a problem
• A Study of SC Administration of Trastuzumab (Herceptin) by SID at Home in HER2-Positive EBC ParticipantsCompletedNCT02040935Phase 3Report a problem
• A Study Evaluating The Safety Of PF-05280014 And Trastuzumab In Healthy Male Volunteers (REFLECTIONS B327-06)CompletedNCT02015156Phase 1Report a problem
• A Study to Assess Preference for Subcutaneous Trastuzumab Treatment in Participants With Human Epidermal Growth Factor Receptor (HER)2-Positive Metastatic Breast Cancer Responding to First-Line Intravenous Trastuzumab for at Least 3 YearsCompletedNCT01810393Phase 3Report a problem
• Pre Operative Trastuzumab in Operable Breast CancerTerminatedNCT01785420Phase 3Report a problem
• A Pharmacokinetic Study Comparing PF-05280014 And Trastuzumab In Healthy Male Volunteers (REFLECTIONS B327-01)CompletedNCT01603264Phase 1Report a problem
• Efficacy Study of Herceptin to Treat HER2-negative CTC Breast CancerCompletedNCT01548677Phase 2Report a problem
• Evaluation of Trastuzumab In Patients With HER2 Positive Persistent Or Recurrent Vulvar Paget's DiseaseWithdrawnNCT01427244Phase 2Report a problem
• Safety Study of ²¹²Pb-TCMC-Trastuzumab Radio ImmunotherapyCompletedNCT01384253Phase 1Report a problem
• Intrathecal Trastuzumab Administration in Metastatic Breast Cancer Patients Developing Carcinomatous MeningitisCompletedNCT01373710Phase 1/2Report a problem
• A Study of Administration of Trastuzumab (Herceptin) by a Single-use Injection Device Versus a Handheld SyringeCompletedNCT01344863Phase 1Report a problem
• Neoadjuvant 5-fluorouracil, Epirubicin and Cyclophosphamide (FEC) Followed by Weekly Paclitaxel and Trastuzumab in Her2 Positive Breast CancerCompletedNCT01340430Phase 2Report a problem
• Feasibility Study of Metronomic Chemotherapy for Locally Advanced Her2- Positive Breast Cancer (TraQ-Me 01)TerminatedNCT01329640Phase 2Report a problem
• Efficacy and Safety Study of Trastuzumab, Paclitaxel and Carboplatin on HER2+ Preoperative Breast CancerStatus unknownNCT01170143Phase 2Report a problem
• Trastuzumab and External Beam Radiation Therapy in Treating Women With Stage III or Stage IV Breast CancerCompletedNCT00943410Phase 2Report a problem
• Trastuzumab in Treating Women With Metastatic Breast CancerCompletedNCT00896376Not applicableReport a problem
• Trastuzumab Therapy in Non-Small Cell Lung Cancer PatientsTerminatedNCT00758134Phase 2Report a problem
• Trastuzumab for HER2 Positive Relapsed/Refractory B-Acute Lymphoblastic Leukemia (B-ALL)TerminatedNCT00724360Phase 2Report a problem
• Trastuzumab Optimization Trial in Breast CancerStatus unknownNCT00637325Phase 3Report a problem
• Combination Chemotherapy and Trastuzumab in Treating Women With Stage I, Stage II, or Stage III HER2-Positive Breast CancerStatus unknownNCT00629278Phase 3Report a problem
• Trastuzumab or Observation After Combination Chemotherapy and Trastuzumab in Treating Patients Undergoing Surgery for Stage II or Stage III Breast CancerStatus unknownNCT00533936Phase 2Report a problem
• T-Cell Response in Patients Receiving Trastuzumab and/or Chemotherapy for HER2-Positive Solid TumorsCompletedNCT00433407Not applicableReport a problem
• Vinorelbine (Oral) Plus Trastuzumab for 1st-line Treatment of HER2/Neu Overexpressing Breast CancerCompletedNCT00433095Phase 2Report a problem
• Randomized Trial With Trastuzumab Versus Observation in Breast Cancer PatientsCompletedNCT00429247Phase 2Report a problem
• Delayed Adjuvant Herceptin® Treatment in Patients With HER-2 Positive Breast CancerTerminatedNCT00427427Phase 2Report a problem
• Trastuzumab for 6 Months or 1 Year in Treating Women With Nonmetastatic Breast Cancer That Can Be Removed By SurgeryCompletedNCT00381901Phase 3Report a problem
• Addition of Herceptin to a Carboplatin-Paclitaxel Regimen in Patients With Ovarian CancerTerminatedNCT00189579Phase 2Report a problem
• Neoadjuvant Herceptin in Patients With Breast CancerTerminatedNCT00133796Phase 2Report a problem
• Trastuzumab in Treating Patients With Metastatic or Recurrent Salivary Gland CancerTerminatedNCT00126607Phase 2Report a problem
• Trastuzumab in Treating Patients With Locally Advanced or Metastatic Synovial SarcomaCompletedNCT00104949Phase 2Report a problem
• Liposomal Doxorubicin and Trastuzumab in Treating Women With Advanced Breast CancerCompletedNCT00006825Phase 1/2Report a problem
• Chemotherapy and Peripheral Stem Cell Transplantation Followed by Trastuzumab in Treating Women With Metastatic Breast CancerWithdrawnNCT00006123Phase 1/2Report a problem
• Trastuzumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial CancerCompletedNCT00006089Phase 2Report a problem
• Trastuzumab in Treating Patients With Recurrent OsteosarcomaCompletedNCT00005033Phase 2Report a problem
• Liposomal Doxorubicin and Trastuzumab in Treating Women With Locally Advanced, Inflammatory, or Metastatic Breast CancerCompletedNCT00004925Phase 1/2Report a problem
• Trastuzumab in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer That Overexpresses HER2CompletedNCT00004883Phase 2Report a problem
• Trastuzumab in Treating Patients With Previously Treated, Locally Advanced, or Metastatic Cancer of the UrotheliumTerminatedNCT00004856Phase 2Report a problem
• Trastuzumab in Treating Patients With Advanced Salivary Gland CancerCompletedNCT00004163Phase 2Report a problem
• Trastuzumab in Treating Patients With Prostate CancerCompletedNCT00003740Phase 2Report a problem

← Trastuzumab